{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-120276","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2021-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.044542+00:00","generated_at":"2026-06-29T01:09:37.479484+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Incyte elects Otis W. Brawley, M.D. to board effective Sept 27, 2021","bullets":["Board size increased to nine; Dr. Brawley elected as director effective September 27, 2021.","Dr. Brawley is Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.","Previously Chief Medical and Scientific Officer of American Cancer Society (2007–2018).","Will receive standard non-employee director compensation as described in 2021 proxy statement.","Dr. Brawley also serves on boards of Lyell Immunopharma and PDS Biotechnology."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-120276","json":"https://secwatch.observer/filing/0001104659-21-120276.json","markdown":"https://secwatch.observer/filing/0001104659-21-120276.md","text":"https://secwatch.observer/filing/0001104659-21-120276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000110465921120276/0001104659-21-120276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000110465921120276/tm2128728d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:09:37.479484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d3d8e6891","claim":"Otis W. Brawley, M.D. was elected as member of the Board of Directors at INCYTE CORP.","evidence_excerpt":"Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000110465921120276/0001104659-21-120276-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}